Victory Capital Management
ODT

Victory Capital Management’s Odonate Therapeutics, Inc. Common Stock ODT Stock Holding History

Victory Capital Management’s Portfolio ODT Stock Details ODT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-18,104
Closed -$500K – 3587
2020
Q1 		$500K Buy
18,104
+9,379
+107% +$273K ﹤0.01% 2089
2019
Q4 		$283K Buy
8,725
+6,116
+234% +$190K ﹤0.01% 2214
2019
Q3 		$68K Buy
+2,609
New +$87.3K ﹤0.01% 2567
2018
Q4 		– Sell
-73,440
Closed -$1.43M – 1829
2018
Q3 		$1.43M Sell
73,440
-3,850
-5% -$78.5K ﹤0.01% 1187
2018
Q2 		$1.71M Sell
77,290
-4,230
-5% -$98.6K ﹤0.01% 1110
2018
Q1 		$1.73M Sell
81,520
-22,930
-22% -$541K ﹤0.01% 1104
2017
Q4 		$2.61M Buy
+104,450
New +$2.47M 0.01% 952

Other funds holding ODT

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return

Victory Capital Management's ODT Position: Q2 2020 in Review

Victory Capital Management sold out of Odonate Therapeutics, Inc. Common Stock (ODT) in Q2 2020, closing a stake of 18,104 shares — an estimated $500K sold.

Victory Capital Management first reported a position in ODT in Q4 2017 and held it in 7 quarters. The position peaked at $2.61M in Q4 2017. 95 funds tracked by Wall St. Rank hold ODT as of Q2 2020.

  • Victory Capital Management reported no remaining Odonate Therapeutics, Inc. Common Stock position as of Q2 2020 after selling out during the quarter.
  • Victory Capital Management sold 18,104 Odonate Therapeutics, Inc. Common Stock shares in Q2 2020, an estimated $500K.
  • Victory Capital Management first reported a position in Odonate Therapeutics, Inc. Common Stock in Q4 2017 and held it in 7 quarters.
  • Victory Capital Management's Odonate Therapeutics, Inc. Common Stock position peaked at $2.61M in Q4 2017.
  • 95 funds tracked by Wall St. Rank held Odonate Therapeutics, Inc. Common Stock as of Q2 2020.

Based on Victory Capital Management's 13F filing for Q2 2020, filed 7 Aug 2020.